CN102483415B - 基于odc1基因型的癌诊断与治疗 - Google Patents

基于odc1基因型的癌诊断与治疗 Download PDF

Info

Publication number
CN102483415B
CN102483415B CN201080031983.5A CN201080031983A CN102483415B CN 102483415 B CN102483415 B CN 102483415B CN 201080031983 A CN201080031983 A CN 201080031983A CN 102483415 B CN102483415 B CN 102483415B
Authority
CN
China
Prior art keywords
patient
purposes according
dfmo
sulindac
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080031983.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102483415A (zh
Inventor
尤金·格尔纳
J·泽尔
C·麦克拉伦
F·麦斯金斯
H·安东卡尔弗
P·A·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Arizona's Public Universities
Original Assignee
University of California
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Arizona's Public Universities filed Critical University of California
Publication of CN102483415A publication Critical patent/CN102483415A/zh
Application granted granted Critical
Publication of CN102483415B publication Critical patent/CN102483415B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080031983.5A 2009-05-14 2010-05-14 基于odc1基因型的癌诊断与治疗 Expired - Fee Related CN102483415B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21621609P 2009-05-14 2009-05-14
US61/216,216 2009-05-14
US21767909P 2009-06-03 2009-06-03
US21768209P 2009-06-03 2009-06-03
US61/217,682 2009-06-03
US61/217,679 2009-06-03
PCT/US2010/034974 WO2010132817A1 (en) 2009-05-14 2010-05-14 Carcinoma diagnosis and treatments, based on odc1 genotype

Publications (2)

Publication Number Publication Date
CN102483415A CN102483415A (zh) 2012-05-30
CN102483415B true CN102483415B (zh) 2015-09-09

Family

ID=43085356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080031983.5A Expired - Fee Related CN102483415B (zh) 2009-05-14 2010-05-14 基于odc1基因型的癌诊断与治疗

Country Status (15)

Country Link
US (4) US8329636B2 (https=)
EP (1) EP2430452B1 (https=)
JP (2) JP6083860B2 (https=)
CN (1) CN102483415B (https=)
AU (1) AU2010248803B2 (https=)
CA (1) CA2761946A1 (https=)
DK (1) DK2430452T3 (https=)
ES (1) ES2507145T3 (https=)
HR (1) HRP20140887T1 (https=)
IL (1) IL216369B (https=)
PL (1) PL2430452T3 (https=)
PT (1) PT2430452E (https=)
SI (1) SI2430452T1 (https=)
SM (1) SMT201400177B (https=)
WO (1) WO2010132817A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2430452T3 (da) 2009-05-14 2014-10-06 Univ Arizona State Carcinom-diagnose og behandlinger, baseret på odc1-genotype
CA2799431A1 (en) * 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
US20120172244A1 (en) 2010-12-20 2012-07-05 Steven Buechler Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
WO2012088146A2 (en) * 2010-12-20 2012-06-28 The University Of Notre Dame Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
CA2889711A1 (en) * 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015195120A1 (en) * 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) * 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2016149261A1 (en) * 2015-03-16 2016-09-22 Personal Genome Diagnostics, Inc. Systems and methods for analyzing nucleic acid
KR20260033630A (ko) 2015-10-30 2026-03-10 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
JP6963271B2 (ja) * 2017-01-20 2021-11-05 国立大学法人東海国立大学機構 イヌの遺伝性消化管腫瘍症の遺伝子診断法
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049859A1 (en) * 1998-03-28 1999-10-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dfmo and sulindac combination in cancer chemoprevention
CN1346282A (zh) * 1998-12-23 2002-04-24 G.D.西尔公司 在肿瘤的治疗中使用环加氧酶－2－抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
US7700568B2 (en) * 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
AU2001285232A1 (en) 2000-08-24 2002-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Alpha-difluoromethylornithine (dfmo) use in the human prostate
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
AU2009333510A1 (en) 2008-12-08 2011-06-30 The Procter & Gamble Company Personal care composition in the form of an article having a hydrophobic surface-resident coating
DK2430452T3 (da) 2009-05-14 2014-10-06 Univ Arizona State Carcinom-diagnose og behandlinger, baseret på odc1-genotype
CA2799431A1 (en) 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049859A1 (en) * 1998-03-28 1999-10-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dfmo and sulindac combination in cancer chemoprevention
CN1346282A (zh) * 1998-12-23 2002-04-24 G.D.西尔公司 在肿瘤的治疗中使用环加氧酶－2－抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Combination Chemoprevention for colon cancer targeting polyamine synthesis and inflammation.;Eugene W. Gerner, Frank L. Meyskens;《Clin Cancer Res》;20090201;第15卷;第758－761页 *
Emerging Concepts in targeting the polyamine metabolic pathway in epithelia cancer chemoprevention and chemotherapy.;Upal K. Basuroy, Eugene W. Gerner;《J Biochem》;20061231;第139卷;第27－33页 *
Functional analysis of human ornithine decarboxylase alleles.;Yongjun Guo等;《Cancer Res》;20001115;第60卷;第6314－6317页 *
Ornithine decarboxylase (Odc)-1 gene polymorphism effects on baseline tissue polyamine levels and adenoma recurrence in a randomized phase III adenoma prevention trial of DFMO+sulindac versus placebo.;J.A.Zell等;《J Clin Oncol》;20080520;第26卷(第15S期);摘要 *
Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.;Richard A. Hubner等;《Clin Cancer Res》;20080415;第14卷;第2303－2309 *
Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.;Elizabeth L. R. Barry等;《J Natl Cancer Inst》;20061018;第98卷;摘要，表4，表5 *
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.;Maria Elena Martinez等;《PNAS》;20030624;第100卷(第13期);第7859－7864页 *
Risk of cardiovascular events in a randomized placebo-controlled,double-blind trial of difluoromethylornithine plus sulindac for the prevention of spordic colorectal adenomas.;Jason A.Zell等;《Cancer Prev Res》;20090303;第2卷;第209－212页 *
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.;Anne R. Simoneau等;《Cancer Epidemiol Biomarkers Prev》;20080229;第17卷;第293页左侧栏倒数第2段，第298页右侧栏第1－3行 *

Also Published As

Publication number Publication date
AU2010248803A1 (en) 2011-12-01
US9937141B2 (en) 2018-04-10
IL216369B (en) 2018-07-31
DK2430452T3 (da) 2014-10-06
SMT201400177B (it) 2015-01-15
ES2507145T3 (es) 2014-10-14
JP2012526852A (ja) 2012-11-01
WO2010132817A1 (en) 2010-11-18
US20100317708A1 (en) 2010-12-16
HK1171082A1 (en) 2013-03-15
HRP20140887T1 (hr) 2014-11-21
SI2430452T1 (sl) 2014-11-28
EP2430452A4 (en) 2013-03-06
CA2761946A1 (en) 2010-11-18
PT2430452E (pt) 2014-09-30
JP6083860B2 (ja) 2017-02-22
CN102483415A (zh) 2012-05-30
JP2016074672A (ja) 2016-05-12
EP2430452B1 (en) 2014-06-25
US20190038584A1 (en) 2019-02-07
EP2430452A1 (en) 2012-03-21
US8329636B2 (en) 2012-12-11
US20160213634A1 (en) 2016-07-28
IL216369A0 (en) 2012-01-31
US9121852B2 (en) 2015-09-01
US20130164751A1 (en) 2013-06-27
PL2430452T3 (pl) 2014-12-31
AU2010248803B2 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
CN102483415B (zh) 基于odc1基因型的癌诊断与治疗
JP6083646B2 (ja) 食事性ポリアミン含量に基づく癌予防及び治療法
JP5833922B2 (ja) 疾患危険因子を同定する方法
EP2726634B1 (en) Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
US20130196955A1 (en) Polymorphisms for predicting disease and treatment outcome
US10655183B2 (en) Carcinoma diagnosis and treatment based on ODC1 genotype
AU2012342682A1 (en) Responsiveness to angiogenesis inhibitors
HK1171082B (en) Carcinoma diagnosis and treatments, based on odci genotype
ES2361018T3 (es) Uso de polimorfismos genéticos para predecir la hepatotoxicidad inducida por fármacos.
US20100286262A1 (en) Ptgs2 haplotypes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1171082

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1171082

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150909

Termination date: 20210514